Remsima®(infliximab) is the first biosimilar monoclonal antibody developed by Celltrion. Remsima® has been developed as intravenous and subcutaneous formulations to provide treatment options for patients with autoimmune disease. In Australia, only the subcutaneous format is marketed as Remsima®SC
This website provides useful information about Remsima®SC.
If you are an Australian healthcare professional, please click the top icon. If you are a patient prescribed with Remsima®SC in Australia, please click the bottom icon. If you do not belong to either category, please contact Celltrion Healthcare, Australia for any appropriate information.
The link you have selected will take you to a third-party website. It is not under the review or control of Celltrion Healthcare and the company does not review or control the contents. The company does not endorse the content, its accuracy or any practices and standards contained in the website.
Please confirm if you wish to follow the link.